Anti-RAS antibodies show poor reliability in recognizing RAS proteins

October 5, 2017 by Will Sansom, University of Texas Health Science Center at San Antonio
Credit: University of Texas Health Science Center at San Antonio

Researchers from the Greehey Children's Cancer Research Institute at UT Health San Antonio co-authored a paper published Sept. 26 in Science Signaling that looks at the reliability of a common research tool to study RAS cancer mutations.

RAS mutations are implicated in several cancers, including lung, colorectal and pancreatic ductal carcinoma. The three RAS genes are the most frequently mutated oncogenes in , implicated in more than a quarter of all human cancers.

In pediatric cancers, mutations that activate the RAS pathway are frequently found in embryonal rhabdomyosarcoma (35 percent of tumors) and recurrent neuroblastoma (60 percent).

The Science Signaling article says that although there is intense interest in studying the development of anti-cancer strategies targeting RAS proteins, the field is held back by poor reliability of anti-RAS to recognize the members of the RAS family of proteins.

These antibodies are a critical research tool, but lack of reliability limits useful—and replicable—study results, the authors noted.

Angelina V. Vaseva, Ph.D., and Peter J. Houghton, Ph.D., director of the Greehey Institute, are the co-authors from UT Health San Antonio. Dr. Vaseva is a visiting scientist from the laboratory of Dr. Channing Der, the senior author on the study performed at the University of North Carolina at Chapel Hill, and done in collaboration with the National Cancer Institute RAS Initiative. Dr. Vaseva conducts research in the Houghton laboratory related to therapeutics of RAS-mutant childhood cancers.

The team from multiple institutions evaluated 22 commercially available anti-RAS antibodies for their capability to recognize RAS subtypes and mutated RAS.

The collaborators identified antibodies that selectively recognize each of the four human RAS proteins in human cancer cells.

This capability is only in Western blot assays, one of the most commonly used research analyses, and not in other research analyses used by laboratories worldwide.

Explore further: Editing genes one by one throughout colorectal cancer cell genome uncovers new drug target

More information: Andrew M. Waters et al. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies, Science Signaling (2017). DOI: 10.1126/scisignal.aao3332

Related Stories

Editing genes one by one throughout colorectal cancer cell genome uncovers new drug target

September 27, 2017
Cancers driven by mutations in the KRAS gene are among the most deadly. For decades, researchers have tried unsuccessfully to directly target mutant KRAS proteins as a means to treat tumors. Instead of targeting mutant KRAS ...

Silencing cancer cell communication may reduce the growth of tumors

January 30, 2017
In several types of cancer, elevated expression of the chemokine receptor CCR4 in tumors is associated with poor patient outcomes. Communication through CCR4 may be one mechanism that cancer cells use to create a pro-tumor ...

New statistical analysis reveals thousands of rare mutations linked with cancer

April 20, 2017
Scientists have identified thousands of previously ignored genetic mutations that, although rare, likely contribute to cancer growth. The findings, which could help pave the way to new treatments, are published in PLOS Computational ...

Researchers home in on mutation profiles of clear cell endometrial cancer

May 9, 2017
In the largest genomics study of clear cell endometrial cancer (CCEC) tumors to date, National Human Genome Research Institute (NHGRI) researchers and their collaborators have identified mutations in the TAF1 gene. They've ...

New role for an old protein: Cancer causer

September 3, 2015
A protein known to play a role in transporting the molecular contents of normal cells into and out of various intracellular compartments can also turn such cells cancerous by stimulating a key growth-control pathway.

Study sheds light on dark side of tumor suppressor gene, p53

April 3, 2017
The gene p53 is the most commonly mutated gene in cancer - it is p53's job to monitor cells for DNA damage and to mark damaged cells for destruction and so cancer cells with mutated DNA must disable p53 before it disables ...

Recommended for you

The complicated biology of garlic

April 26, 2018
Researchers today generally agree that eating garlic, used for thousands of years to treat human disease, can reduce the risk of developing certain kinds of cancers, cardiovascular disease, and type 2 diabetes. Nevertheless, ...

CRISPR-based diagnostic SHERLOCK optimized for rapid use during viral outbreaks

April 26, 2018
In a paper published today in Science, researchers at Broad Institute of MIT and Harvard report a new tool that engineers the CRISPR-based diagnostic SHERLOCK for rapid outbreak response. The updates to SHERLOCK, which was ...

Noninvasive brain tumor biopsy on the horizon

April 26, 2018
Taking a biopsy of a brain tumor is a complicated and invasive surgical process, but a team of researchers at Washington University in St. Louis is developing a way that allows them to detect tumor biomarkers through a simple ...

Too liberal use of oxygen increases risk of death in acutely ill adult patients

April 26, 2018
McMaster University researchers have found there is such a thing as too much oxygen for acutely ill adults.

Lab-on-a-chip delivers critical immunity data for vulnerable populations

April 25, 2018
For millions of displaced people around the world—many of them refugees, living in temporary shelters under crowded conditions—an outbreak of disease is devastating. Each year, the measles virus kills more than 134,000 ...

Want new medicines? You need fundamental research

April 25, 2018
Would we be wise to prioritize "shovel-ready" science over curiosity-driven, fundamental research programs? Would that set the stage for the discovery of more new medicines over the long term?

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.